84 F. Supp. 3d 1367

IN RE: NARCONON DRUG REHABILITATION MARKETING, SALES PRACTICES AND PRODUCTS LIABILITY LITIGATION.

MDL No. 2598.

United States Judicial Panel on Multidistrict Litigation

Feb. 5, 2015.

Before SARAH S. VANCE, Chair, MARJORIE O. RENDELL, CHARLES R. BREYER, ELLEN SEGAL HUVELLE, R. DAVID PROCTOR, and CATHERINE D. PERRY, Judges of the Panel.

ORDER DENYING TRANSFER

SARAH S. VANCE, Chairman.

Before the Panel:* Plaintiffs in the District of Nevada Welch action move under 28 U.S.C. § 1407 to centralize pretrial proceedings in this litigation in the District of Nevada or, alternatively, in the Southern District of California. This litigation consists of twenty-one actions pending in the Central, Northern, and Southern Districts of California, the District of Colorado, and the District of Nevada, as listed on Schedule A.1 Defendants Association for Better Living and Education International (ABLE), Narconon International (NI), Narconon Fresh Start, Narconon Western United States, and Narconon Freedom Center (collectively, Narconon) oppose centralization. Alternatively, should we centralize this litigation, Narconon suggests that the Southern District of Califor-nia be selected as the transferee district.

On the basis of the papers filed and the hearing session held, we conclude that centralization will not serve the convenience of the parties and witnesses or further the just and efficient conduct of this litigation. These actions share some common factual questions relating to plaintiffs’ allegations that the Narconon Program — -a drug rehabilitation program that plaintiffs allege consists solely of the reading of literature from the Scientology religion and a sauna detoxification program — does not meet the applicable standard of care for treating substance abuse and that defendants misrepresented the Narconon program’s efficacy and its connection to Scientology. We are not convinced, though, that these common issues are sufficiently complex or numerous to warrant the creation of an MDL. These actions are primarily fraud actions and will involve significant case-specific facts, such as the specific repre*1368sentations regarding the Narconon Program made to each plaintiff, the conditions at the different facilities attended by the plaintiffs at different times, and the widely varying injuries allegedly suffered by plaintiffs. The necessary discovery and pretrial practice in each action also will differ from action to action due to the different state and federal laws asserted in each action. In addition, several cases involve arbitration clauses and, to the extent that plaintiffs pose capacity defenses to those clauses, that inquiry will be individualized. Further, the common defendants — ABLE and NI — have been dismissed from at least eight of these actions to date. Thus, on the present record, it appears that individualized facts may predominate over the common factual issues in this litigation. See In re Signal Int’l LLC Human Trafficking Litig., MDL No. 2554, 38 F.Supp.3d 1390, 1390, 2014 WL 4050056, at *1 (J.P.M.L. Aug. 12, 2014) (denying centralization because, inter alia, “individualized facts very well may predominate over the common factual issues alleged by plaintiffs”).

Furthermore, none of the actions is a class action, which limits the scope for inconsistent pretrial rulings and practice to issues pertaining to discovery and scheduling. Plaintiffs in all the actions on the motion are represented by common counsel,2 while defendants purportedly have retained liaison counsel to coordinate the litigation. At oral argument; counsel for the defendants confirmed their willingness to coordinate with respect to discovery of any common third-party or Narconon witnesses. These circumstances suggest that voluntary cooperation and coordination among the parties and the involved courts, particularly given the number of actions, is a preferable alternative to centralization to address any possibility of duplicative discovery or inconsistent pretrial rulings. See, e.g., In re Eli Lilly & Co. (Cephalexin Monohydrate) Patent Litig., 446 F.Supp. 242, 244 (J.P.M.L.1978); see also Manual for Complex Litigation, Fourth, § 20.14 (2004).

IT IS THEREFORE ORDERED that the motion for centralization of these actions is denied.

SCHEDULE A

MDL No. 2598 — IN RE: NARCONON DRUG REHABILITATION MARKETING, SALES PRACTICES AND PRODUCTS LIABILITY LITIGATION

Central District of California

LOVETT v. ASSOCIATION OF BETTER LIVING AND EDUCATION INTERNATIONAL, ET AL., C.A. No. 2:14-06430

NORD-SHAFER, ET AL. v. ASSOCIATION OF BETTER LIVING AND EDUCATION INTERNATIONAL, ET AL., C.A. No. 2:14-06438

Northern District of California

O'CONNELL, ET AL. v. NARCONON OF NORTHERN CALIFORNIA, ET AL. C.A. No. 5:14-02660

Southern District of California

AMATO v. NARCONON FRESH START, ET AL., C.A. No. 3:14-00588 *1369 BURCHETT, ET AL. v. NARCONON FRESH START, ET AL., C.A. No. 3:14-01678

KELLER, ET AL. v. NARCONON FRESH START, ET AL., C.A. No. 3:14-02168

HENNING, ET AL. v. NARCONON FRESH START, ET AL., C.A. No. 3:14-02379

District of Colorado

MOTT, ET AL. v. NARCONON FRESH START, C.A. No. 1:14-01293

MATTHYS, ET AL. v. NARCONON FRESH START, ET AL., C.A. No. 1:14-01304

LEVY v. NARCONON FRESH START, ET AL., C.A. No. 1:14-01591

VAIRO, ET AL. v. NARCONON FRESH START, ET AL., C.A. No. 1:14-02748

COURSON, ET AL. v. NARCONON FRESH START, ET AL., C.A. No. 1:14-02768

District of Nevada

WELCH, ET AL. v. NARCONON FRESH START, C.A. No. 2:14-00167

TARR, ET AL. v. NARCONON FRESH START, C.A. No. 2:14-00283

GEANACOPULOS, ETAL. v. NARCONON FRESH START, ET AL., C.A. No. 2:14-00629

YATES, ET AL. v. NARCONON FRESH START, ET AL., C.A. No. 2:14-00837

WINCHELL, ET AL. v. NARCONON FRESH START, ET AL., C.A. No. 2:14-00851

McCLURE, ET AL. v. NARCONON FRESH START, ET AL., C.A. No. 2:14-00995

TINO, ETAL. v. NARCONON FRESH START, ET AL., C.A. No. 2:14-01083

KOSLOW, ET AL. v. NARCONON FRESH START, ET AL., C.A. No. 2:14-01588

MARTIN, ET AL. v. NARCONON FRESH START, ET AL., C.A. No. 2:14-01599

In re Narconon Drug Rehabilitation Marketing, Sales Practices & Products Liability Litigation
84 F. Supp. 3d 1367

Case Details

Name
In re Narconon Drug Rehabilitation Marketing, Sales Practices & Products Liability Litigation
Decision Date
Feb 5, 2015
Citations

84 F. Supp. 3d 1367

Jurisdiction
United States

References

Referencing

Nothing yet... Still searching!

Referenced By

Nothing yet... Still searching!